Search

Relay Therapeutics Inc

Fermé

SecteurSoins de santé

18.84 -1.87

Résumé

Variation du prix de l'action

24h

Actuel

Min

18.6

Max

18.98

Chiffres clés

By Trading Economics

Revenu

-10M

-84M

Ventes

-2.7M

350K

BPA

-0.41

Marge bénéficiaire

-23,916.286

Employés

202

EBITDA

-10M

-83M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+46.63% upside

Dividendes

By Acuity

Prochains Résultats

5 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

84M

4.2B

Ouverture précédente

20.71

Clôture précédente

18.84

Sentiment de l'Actualité

By Acuity

50%

50%

120 / 339 Classement par Healthcare

Relay Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 sept. 2026, 20:06 UTC

Relay Therapeutics Inc shares fell sharply after an early peak, trading below its 20-day moving average and near the lower end of its one-month range.

17 sept. 2026, 19:46 UTC

Relay Therapeutics Inc is trading higher, having reached a peak earlier before pulling back, and has gained since Wednesday's close.

16 sept. 2026, 20:13 UTC

Relay Therapeutics Inc saw modestly lower trading during after-market hours, remaining unchanged since Wednesday's close and below its 20-day moving average.

15 sept. 2026, 19:46 UTC

Relay Therapeutics Inc shares are lower, reflecting negative market sentiment after the NY Empire State Manufacturing Index fell sharply to 7.6 for September.

14 sept. 2026, 20:21 UTC

Relay Therapeutics Inc. shares advanced in after-market trading, rebounding from earlier lows and reflecting a shift within a routine range since Monday's close.

10 sept. 2026, 19:16 UTC

Relay Therapeutics Inc is trading higher, recovering from an earlier dip. No specific news was identified, though broader market sentiment may be influencing shares.

9 sept. 2026, 23:31 UTC

Relay Therapeutics Inc is trading higher in after-market hours, advancing since Wednesday's close despite a broader market decline amid rising oil prices and inflation concerns.

8 sept. 2026, 20:07 UTC

News

Relay Therapeutics shares are higher, continuing an upward trend since Friday's close, though they remain below the 20-day moving average.

2 sept. 2026, 20:08 UTC

News

Relay Therapeutics will participate in two investor conferences in September 2026. Shares are trading roughly flat since Tuesday's close, below the 20-day moving average.

31 août 2026, 20:07 UTC

Relay Therapeutics shares are lower today amid broader market pressures and concerns about inflation following the Jackson Hole Economic Symposium.

28 août 2026, 21:51 UTC

Relay Therapeutics Inc is trading higher in after-market hours, rebounding from three consecutive lower sessions. No specific news was identified for this movement.

27 août 2026, 22:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, declining from earlier gains amid broader weakness and three consecutive sessions of losses.

26 août 2026, 20:08 UTC

Relay Therapeutics Inc is trading lower today amid broader market declines, influenced by inflation data that exceeded expectations and may impact Federal Reserve policy.

25 août 2026, 23:41 UTC

Relay Therapeutics Inc shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

24 août 2026, 19:56 UTC

Social Media

Relay Therapeutics is testing a buy point at $20.79, reflecting ongoing interest. The stock remains higher since Friday's close despite an earlier pullback.

21 août 2026, 21:01 UTC

Relay Therapeutics Inc is trading higher in after-market hours, up significantly since Friday's close and above its 20-day moving average.

20 août 2026, 20:02 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower today, influenced by a decline in the broader Biotechnology sector and significant market volatility. Trading volume remains unusually high.

19 août 2026, 23:01 UTC

Relay Therapeutics Inc is trading higher in after-market hours, positioned near the upper end of its one-month range and above its 20-day moving average.

18 août 2026, 22:26 UTC

Relay Therapeutics Inc. shares traded lower after market hours, reflecting broader market pressure from rising bond yields and inflation concerns.

17 août 2026, 19:36 UTC

Social Media
News

Relay Therapeutics Inc is trading higher amid a Phase 3 trial for its breast cancer treatment and a $53 million investment from Baker Bros.

14 août 2026, 21:51 UTC

Social Media

Relay Therapeutics Inc is gaining in after-market trading, supported by social media discussions and a significant portfolio stake from Perceptive Advisors.

13 août 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc is trading lower, reflecting broader declines in the biotechnology sector amid fluctuations and rising initial jobless claims.

10 août 2026, 19:56 UTC

News
Social Media

Relay Therapeutics shares are higher after Citizens raised its price target to $26, citing confidence in the company's Phase 3 trials.

7 août 2026, 20:06 UTC

News
Correlated Moves
Social Media

Barclays raised its price target on Relay Therapeutics to $30.00, contributing to positive sentiment amid ongoing analyst support following the company's Q2 earnings.

6 août 2026, 23:02 UTC

News

Relay Therapeutics shares are lower in after-market hours following disappointing Q2 results, including a net loss of $83.7 million and revenue of $350,000.

5 août 2026, 22:26 UTC

Relay Therapeutics Inc. shares advanced in after-market trading, maintaining a position above its 20-day moving average amid broader macroeconomic sentiment.

4 août 2026, 19:26 UTC

Correlated Moves

Relay Therapeutics Inc is trading higher during Tuesday's session, continuing its upward trend since Monday's close. Broader market sentiment supports this performance.

3 août 2026, 21:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, continuing a downward trend amid three consecutive sessions of declines and no specific news.

31 juil. 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower in Friday's session, reflecting broader declines in the biotech sector amid rising yields and inflation concerns.

30 juil. 2026, 17:36 UTC

Correlated Moves
News

Relay Therapeutics Inc is rising as it advances its PI3Kα inhibitor for breast cancer treatment, drawing renewed interest and nearing IPO levels.

Comparaison

Variation de prix

Relay Therapeutics Inc prévision

Objectif de Prix

By TipRanks

46.63% hausse

Prévisions sur 12 Mois

Moyen 27.625 USD  46.63%

Haut 31 USD

Bas 20 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

9

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

120 / 339Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.